United Therapeutics Corp. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 1,233 shares of the company’s stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $132.81, for a total transaction of $163,754.73. Following the sale, the chief executive officer now directly owns 1,373 shares of the company’s stock, valued at approximately $182,348.13. The sale was disclosed in a filing with the SEC, which is available at this link.

Shares of United Therapeutics Corp. (NASDAQ:UTHR) opened at 125.61 on Thursday. The firm has a 50 day moving average of $122.42 and a 200-day moving average of $118.39. The stock has a market capitalization of $5.33 billion, a P/E ratio of 8.50 and a beta of 1.39. United Therapeutics Corp. has a 12 month low of $97.52 and a 12 month high of $164.04.

United Therapeutics Corp. (NASDAQ:UTHR) last issued its quarterly earnings results on Thursday, October 27th. The biotechnology company reported $4.36 EPS for the quarter, topping analysts’ consensus estimates of $3.38 by $0.98. The business earned $408.20 million during the quarter, compared to the consensus estimate of $400.58 million. United Therapeutics Corp. had a net margin of 44.40% and a return on equity of 41.78%. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.55 earnings per share. Analysts forecast that United Therapeutics Corp. will post $16.29 earnings per share for the current year.

Insider Buying and Selling by Quarter for United Therapeutics Corp. (NASDAQ:UTHR)

COPYRIGHT VIOLATION WARNING: “Martine A. Rothblatt Sells 1,233 Shares of United Therapeutics Corp. (UTHR) Stock” was first published by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of United States and international copyright laws. The legal version of this report can be accessed at http://www.dailypolitical.com/2016/12/01/martine-a-rothblatt-sells-1233-shares-of-united-therapeutics-corp-uthr-stock.html.

Several large investors have recently modified their holdings of the company. Daiwa Securities Group Inc. boosted its stake in United Therapeutics Corp. by 16.7% in the second quarter. Daiwa Securities Group Inc. now owns 1,050 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 150 shares in the last quarter. Nordea Investment Management AB boosted its stake in United Therapeutics Corp. by 18.7% in the second quarter. Nordea Investment Management AB now owns 1,208 shares of the biotechnology company’s stock valued at $128,000 after buying an additional 190 shares in the last quarter. Piedmont Investment Advisors LLC bought a new stake in United Therapeutics Corp. during the third quarter valued at about $201,000. BancorpSouth Inc bought a new stake in United Therapeutics Corp. during the third quarter valued at about $224,000. Finally, Zweig DiMenna Associates LLC bought a new stake in United Therapeutics Corp. during the third quarter valued at about $224,000.

Several equities analysts have weighed in on the stock. Barclays PLC lowered shares of United Therapeutics Corp. from an “equal weight” rating to an “underweight” rating and decreased their target price for the company from $115.00 to $100.00 in a report on Tuesday. Wedbush reiterated an “outperform” rating and issued a $229.00 target price on shares of United Therapeutics Corp. in a report on Friday, November 4th. Cowen and Company set a $144.00 target price on shares of United Therapeutics Corp. and gave the company a “buy” rating in a report on Thursday, October 27th. Ladenburg Thalmann upgraded shares of United Therapeutics Corp. from a “neutral” rating to a “buy” rating and boosted their target price for the company from $128.00 to $138.00 in a report on Friday, October 28th. Finally, Zacks Investment Research lowered shares of United Therapeutics Corp. from a “buy” rating to a “hold” rating in a report on Thursday, October 20th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $133.42.

About United Therapeutics Corp.

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb).

5 Day Chart for NASDAQ:UTHR

Receive News & Ratings for United Therapeutics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corp. and related companies with MarketBeat.com's FREE daily email newsletter.